ArticleNature2017
Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.Probiotics and antimicrobial proteins · 2026Review
- Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells.Scientific reports · 2025Article
- Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review.Frontiers in oncology · 2025Article
- Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.Molecular cancer · 2023Article
- Recent advances in sonodynamic immunotherapy.Journal of cancer research and clinical oncology · 2023Review
- Review
- Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis.Journal of nanobiotechnology · 2022Article
- Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.Frontiers in immunology · 2022Article
- IFN-γ and CD38 in Hyperprogressive Cancer Development.Cancers · 2021Review
- Article
- Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.International journal of nanomedicine · 2021Article
- Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.Nature communications · 2020Article
- Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy.BMC medical informatics and decision making · 2020Article
- Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.Journal of immunology research · 2020Review
- POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer.Oncology letters · 2020Article
- Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.Nature communications · 2019Article
- Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.ESMO open · 2019Article
- Hyperprogressive disease: recognizing a novel pattern to improve patient management.Nature reviews. Clinical oncology · 2018Review
- Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.Frontiers in oncology · 2018Review
- Immuno-Oncology: Emerging Targets and Combination Therapies.Frontiers in oncology · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.